Evolving concepts

Immunity in oncology from targets to treatments

Hina Khan, Rasim A. Gucalp, Iuliana Shapira

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells.Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen- 4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effectorimmune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.

Original languageEnglish (US)
Article number847383
JournalJournal of Oncology
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Immunity
Neoplasms
CTLA-4 Antigen
Therapeutics
Antibodies
Non-Small Cell Lung Carcinoma
Melanoma
Clinical Trials
Ligands
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Evolving concepts : Immunity in oncology from targets to treatments. / Khan, Hina; Gucalp, Rasim A.; Shapira, Iuliana.

In: Journal of Oncology, Vol. 2015, 847383, 2015.

Research output: Contribution to journalArticle

@article{754bc6b6f8774657a0b76459884899bf,
title = "Evolving concepts: Immunity in oncology from targets to treatments",
abstract = "Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells.Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen- 4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effectorimmune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.",
author = "Hina Khan and Gucalp, {Rasim A.} and Iuliana Shapira",
year = "2015",
doi = "10.1155/2015/847383",
language = "English (US)",
volume = "2015",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Evolving concepts

T2 - Immunity in oncology from targets to treatments

AU - Khan, Hina

AU - Gucalp, Rasim A.

AU - Shapira, Iuliana

PY - 2015

Y1 - 2015

N2 - Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells.Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen- 4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effectorimmune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.

AB - Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells.Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen- 4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effectorimmune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.

UR - http://www.scopus.com/inward/record.url?scp=84929377561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929377561&partnerID=8YFLogxK

U2 - 10.1155/2015/847383

DO - 10.1155/2015/847383

M3 - Article

VL - 2015

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 847383

ER -